Kristina Fuhr

Dr. Kristina Fuhr

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
KFKristina Fuhr
Kristina Fuhr
CMChristoph Meisner
Christoph Meisner
ABAngela Broch
Angela Broch
BCBarbara Cyrny
Barbara Cyrny
JHJuliane Hinkel
Juliane Hinkel
ABAnil Batra
Anil Batra

9 June 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
WLWolfgang Lutz
Wolfgang Lutz
AAAlice Arndt
Alice Arndt
JRJulian Rubel
Julian Rubel
TBThomas Berger
Thomas Berger
JSJohanna Schröder
Johanna Schröder
SMSteffen Moritz
Steffen Moritz
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

21 October 2021 in Psychology and Psychotherapy: Theory, Research and Practice
Verified
Journal Article
Open access
PDF file
KFKristina Fuhr
Kristina Fuhr
DWDustin Werle
Dustin Werle
ABAnil Batra
Anil Batra
Objectives: Previous studies reported about the influence of early changes on treatment response. However, the question of whether early changes can predict the subsequent course of depressive symptoms during treatment with psychotherapy has not yet been clearly answered. We aimed to investigate whether symptom course in the first weeks at the level of individual session can predict the further symptom progression on a session to session level during psychotherapy treatment in patients with Major Depression (MD). Design: Monocentric randomized controlled trial with psychotherapeutic treatment either with cognitive‐behavioural therapy (CBT) or hypnotherapy (HT). The longitudinal course of weekly depressive symptoms during the six months treatment period was examined. Methods: In this RCT with 152 randomized patients suffering from current mild‐to‐moderate MD, depressive symptoms were assessed on a weekly basis during the 20 sessions’ treatment with individual psychotherapy. We only included patients for which sufficient data for our analysis were available. Three different linear and quadratic mixed model analyses with random effects for each patient were tested: Early change was defined as the individual percentage symptom change during the first two, three, four and five weeks. Symptoms from session four, five, six and seven onward were predicted using different models, with early change added to the model in a final step. Calculating all models separately for CBT and HT lead to comparable results. Result: A slow symptom decrease after session four, five, six, seven onward to the end of the treatment was found. However, adding early change to the model, had no effect on the further symptom course in all models. Conclusion: Symptom changes at early stages of psychotherapy should not be considered as being predictive for further symptom course. Practitioner points: The individual early symptom change in a treatment with psychotherapy in the first two, three, four, or five weeks of treatment does not predict the subsequent symptom course from session four, five, six, or seven onward at a session to session level. Symptom changes at early stages of psychotherapy should not be considered as being predictive for further symptom course. We found a symptom reduction ranging from 3% to 16% in the first two, three, four, or five weeks. Treatment response between the first and last therapy session was found in 54.5%, the number of remitted patients (with PHQ‐9 scores < 5) was 44.7%. A small symptom improvement of between 0.21 and 0.42 points in the PHQ‐9 scores per week in later stages of psychotherapy is likely in all patients (with and without early symptom improvement).

10 August 2023 in Frontiers in Psychology
Verified
Journal Article
Open access
KFKristina Fuhr
Kristina Fuhr
ABAnnika Bender
Annika Bender
AWAriane Wiegand
Ariane Wiegand
PJPaul Janouch
Paul Janouch
MDMarta Drujan
Marta Drujan
ABAnil Batra
Anil Batra
A number of case studies describing hypnotherapy in the treatment of anxiety disorder patients have already been published. Only a few randomized controlled trials (RCTs) investigated the efficacy of hypnotherapy but focused mainly on symptoms rather than specific mental disorders. The goal of this study was to investigate whether hypnotherapy (HT) was superior to a waitlist control group (WL) in the reduction of agoraphobia-related symptoms. Further goals were to report the feasibility of hypnotherapy as well as attrition and completion rates and detect (epi-)genetic variables, which might play a role in treatment outcome. This pilot study was based on a monocentric two-armed randomized controlled rater-blind clinical trial that was conducted between 2018 and 2020 with a waitlist control group. A total of 36 patients diagnosed with agoraphobia were randomized to either HT or WL. Patients in HT received individual outpatient treatment with hypnotherapy with 8 to 12 sessions for a period of 3 months. Patients in WL received HT after 3 months. Agoraphobia-related symptoms were assessed at baseline, after the treatment, and 3 months later in both groups with a clinician rating. The primary hypothesis concerning the difference between groups in the individual percentage symptom reduction could be confirmed in the intention-to-treat, not the per-protocol sample. Additionally, we applied repeated-measures analyses of variance and found a higher symptom decrease in HT compared with WL patients in three of the five imputed datasets. The dropout rate was low, and satisfaction with the treatment was high. HT patients experienced a strong symptom reduction after receiving hypnotherapy. WL patients improved slightly during the waiting period. The COMT Val108/158Met genotype had an effect on the agoraphobia-related symptoms as well as on COMT DNA methylation levels. This is the first study to indicate that hypnotherapy performed better than a waitlist control group regarding the reduction in anxiety symptoms in an RCT. Future studies should confirm the efficacy of hypnotherapy and compare the treatment with a standard treatment for anxiety disorders in a larger trial. Future studies should also investigate whether hypnotic susceptibility is associated with COMT Val108/158Met genotype and could predict treatment success for HT.Clinical trial registration: https://classic.clinicaltrials.gov/ct2/show/NCT03684577, identifier: NCT03684577.

30 December 2025 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
MDMarta Drujan
Marta Drujan
KGKaltrina Gashi
Kaltrina Gashi
AFAndreas J. Fallgatter
Andreas J. Fallgatter
ABAnil Batra
Anil Batra
KFKristina Fuhr
Kristina Fuhr
Imagery rescripting (IR) has been shown to be effective for emotion regulation in both patients with mental disorders and in experimental settings. However, the effects of rumination on emotion regulation remain ambiguous, with some studies classifying rumination as an adaptive emotion regulation strategy and others as maladaptive. In this pilot study, we aimed to compare the effect of IR with rumination on emotion regulation following sad autobiographical recall. We expected IR to be more effective in recovering positive affect compared to rumination and a control group. In an online experiment, 70 healthy students were randomly assigned to IR, rumination, or a passive control group after recalling a sad autobiographical memory. Mood was assessed using the Positive and Negative Affect Schedule (PANAS) before and after the intervention. In this study, IR was superior to rumination (p = 0.033) in recovering PA after sad autobiographical recall. Therefore, IR affects mood recovery positively after recalling a sad autobiographical memory. Rumination resulted in prolonged impairment in mood and therefore should be regarded as a maladaptive emotion regulation strategy.

24 July 2023 in PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
Verified
Journal Article
Closed access
PDF file
KFKristina Fuhr
Kristina Fuhr
VBVictoria Maren Beier
Victoria Maren Beier
CMChristoph Meisner
Christoph Meisner
ABAnil Batra
Anil Batra
Zusammenfassung: Ziel der Studie Die wissenschaftliche Anerkennung der Hypnotherapie ist für bestimmte psychische Störungen immer noch nicht bestätigt. Im Rahmen einer randomisiert-kontrollierten Studie, die die Wirksamkeit der Hypnotherapie (HT) mit der Kognitiven Verhaltenstherapie (KVT) bei leichten bis mittelschweren depressiven Episoden verglich, konnte eine Nicht-Unterlegenheit der HT gegenüber der KVT gefunden werden. Ziel dieser Studie war die Untersuchung der depressiven Symptomatik im Langzeitverlauf dreieinhalb Jahre nach Behandlungsende. Methodik Die insgesamt 152 randomisierten Patientinnen und Patienten hatten über einen Zeitraum von sechs Monaten ambulante Einzelpsychotherapiesitzungen mit 16 bis 20 Sitzungen erhalten. Dreieinhalb Jahre nach Behandlungsende wurden alle zu einer Nachbefragung eingeladen, bei der depressive Symptome im Selbst- und Fremdurteil erfasst wurden. In die Per-Protokoll (PP) Analyse wurden nur die Personen mit vorhandenen Daten eingeschlossen, es erfolgte jedoch ein Vergleich der Merkmale mit Personen ohne eine Teilnahme an der Nachbefragung. Eine zusätzliche Intention-to-treat (ITT) Analyse wurde mit multipel imputierten Daten der fehlenden Werte durchgeführt. Ergebnisse Insgesamt 71 Personen (46,7%) nahmen an der erneuten Befragung teil. Die Nicht-Unterlegenheit der HT im Vergleich zur KVT bezogen auf die prozentuale Symptomverbesserung im Fremdurteil konnte in der PP-, aber auch in der ITT-Stichprobe bestätigt werden. Die Symptomverbesserungen im Selbst- und Fremdurteil bei Therapieende blieben bei der Nachbefragung bestehen. Responseraten und Remissionsraten werden für das Selbst- als auch die Fremdurteile berichtet. Schlussfolgerung In dieser Studie konnten Hinweise darauf gefunden werden, dass die HT auch langfristig der KVT bei der Behandlung von Depressionen nicht unterlegen war. Weitere Studien sollten die Wirksamkeit der HT an größeren multizentrischen Stichproben untersuchen sowie Prädiktoren für einen individuellen Therapieerfolg identifizieren.